Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities
Hemonnot AL, Hua J, Ulmann L, Hirbec H.. Frontiers in aging neuroscience, 2019-08-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Microglia are the resident macrophages of the central nervous system. They play key roles in brain development, and physiology during life and aging. Equipped with a variety of molecular sensors and through the various functions they can fulfill, they are critically involved in maintaining the brain's homeostasis. In Alzheimer disease (AD), microglia reaction was initially thought to be incidental and triggered by amyloid deposits and dystrophic neurites. However, recent genome-wide association studies have established that the majority of AD risk loci are found in or near genes that are highly and sometimes uniquely expressed in microglia. This leads to the concept of microglia being critically involved in the early steps of the disease and identified them as important potential therapeutic targets. Whether microglia reaction is beneficial, detrimental or both to AD progression is still unclear and the subject of intense debate. In this review, we are presenting a state-of-knowledge report intended to highlight the variety of microglial functions and pathways shown to be critically involved in AD progression. We first address both the acquisition of new functions and the alteration of their homeostatic roles by reactive microglia. Second, we propose a summary of new important parameters currently emerging in the field that need to be considered to identify relevant microglial targets. Finally, we discuss the many obstacles in designing efficient therapeutic strategies for AD and present innovative technologies that may foster our understanding of microglia roles in the pathology. Ultimately, this work aims to fly over various microglial functions to make a general and reliable report of the current knowledge regarding microglia's involvement in AD and of the new research opportunities in the field.
What this study adds
Evidence grade: Low
This is a narrative review. This review reports that most Alzheimer disease risk loci are found in or near genes highly expressed in microglia, leading to the idea that microglia are involved early in the disease and are potential therapeutic targets. It also states that whether microglia reactions are beneficial, detrimental, or both remains unclear and under debate, so no treatment is established.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hemonnot, A. L., Hua, J., Ulmann, L., & Hirbec, H. (2019). Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2019.00233
Vancouver
Hemonnot AL, Hua J, Ulmann L, Hirbec H. Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. Frontiers in aging neuroscience. 2019. doi:10.3389/fnagi.2019.00233. PMID: 31543810.
BibTeX
@article{hemonnot2019-31543810,
author = {Hemonnot, A. L. and Hua, J. and Ulmann, L. and Hirbec, H.},
title = {{Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities}},
journal = {Frontiers in aging neuroscience},
year = {2019},
doi = {10.3389/fnagi.2019.00233},
pmid = {31543810},
url = {https://doi.org/10.3389/fnagi.2019.00233}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In this review, we are presenting a state-of-knowledge report intended to highlight the variety of microglial functions and pathways shown to be critically involved in AD progression.
- We first address both the acquisition of new functions and the alteration of their homeostatic roles by reactive microglia.
- Second, we propose a summary of new important parameters currently emerging in the field that need to be considered to identify relevant microglial targets.
- Finally, we discuss the many obstacles in designing efficient therapeutic strategies for AD and present innovative technologies that may foster our understanding of microglia roles in the pathology.
- Ultimately, this work aims to fly over various microglial functions to make a general and reliable report of the current knowledge regarding microglia's involvement in AD and of the new research opportunities in the field.
Why it matters
This review reports that most Alzheimer disease risk loci are found in or near genes highly expressed in microglia, leading to the idea that microglia are involved early in the disease and are potential therapeutic targets. It also states that whether microglia reactions are beneficial, detrimental, or both remains unclear and under debate, so no treatment is established.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | 2 / 4 | Frontiers in Aging Neuroscience: journal h-index 174 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 298 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 33.1 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 4 / 6 | Cited 17.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 3 / 4 | Cited 66 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Hélène Hirbec: h-index 22 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31543810) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fnagi.2019.00233
- PubMed: 31543810
- Original source →
- Free full text: Frontiers in Aging Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 45.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics from nearby years
Also in Genetics
210 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.